Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Crescita Therapeutics
Deal Size : $0.5 million
Deal Type : Termination
Crescita Announces Mutual Termination of Licensing Agreement with Croma for Pliaglis
Details : Under the mutual agreement, Crescita has terminated its commercialization and development license agreement with CROMA that granted Croma exclusive rights to market Pliaglis in Germany, UK etc.
Product Name : Pliaglis
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 23, 2025
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Crescita Therapeutics
Deal Size : $0.5 million
Deal Type : Termination
Lead Product(s) : Hyaluronic Acid,Lidocaine
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Princess Volume Plus (hyaluronic acid) dermal filler and Lidocaine with the intention to confirm the efficacy and safety in respect of mid-facial volume insufficiency and/or mid-facial profile deficient participants.
Product Name : Princess Volume Plus
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2023
Lead Product(s) : Hyaluronic Acid,Lidocaine
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Saypha Volume Lidocaine
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saypha® VOLUME Lidocaine for Midface Augmentation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide-drug Conjugate
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : Saypha Volume Lidocaine
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Crescita Therapeutics
Deal Size : $1.4 million
Deal Type : Licensing Agreement
Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis®
Details : Croma will promote Pliaglis directly to physicians through its sales network consisting of approximately 130 members across the Territories. As part of the agreement, Crescita is eligible to receive a combination of upfront, cumulative sales and other mi...
Product Name : Pliaglis
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 28, 2021
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Crescita Therapeutics
Deal Size : $1.4 million
Deal Type : Licensing Agreement
Lead Product(s) : Lidocaine
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 08, 2021
Lead Product(s) : Lidocaine
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Saypha Volume Lidocaine
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saypha® Volume LIdocaine in Nasolabial Folds
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide-drug Conjugate
Upfront Cash : Inapplicable
May 12, 2021
Lead Product(s) : Saypha Volume Lidocaine
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Hugel
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 21, 2021
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Hugel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : China National Biotech Group
Deal Size : Undisclosed
Deal Type : Collaboration
Croma Establishes New Joint Venture in China
Details : The joint venture comprises Croma's Hyaluronic Acid Filler Princess® VOLUME and additional filler and facial aesthetic products and CNBG's multi-channel distribution, marketing experience and synergistic products, specifically its botulinum toxin produc...
Product Name : Princess Volume Plus
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 15, 2020
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : China National Biotech Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Croma’s botulinum toxin submission in Europe is based on 2 completed randomized, placebo-controlled Phase III pivotal trials (BLESS I and II) that enrolled a total of 917 subjects in Europe and the US.
Product Name : BoNT/A-DP
Product Type : Protein
Upfront Cash : Inapplicable
August 07, 2020
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 14, 2019
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable